Your account is not claimed yet. You can sign up with ORCID to claim your account.

Virginia Arechavala-Gomeza (V Arechavala-Gomeza)

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Venues

Nucleic acid therapeutics

Neuropathology and applied neurobiology

EMBO molecular medicine

Genes

Ikerbasque, Basque Foundation for Science

King's College London (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Ikerbasque, Basque Foundation for Science Jan 1o 2019

Spain

Ikerbasque Professor

Education History

King's College London

United Kingdom

PHD

Publications

Haiyan Zhou, Virginia Arechavala-Gomeza, Alejandro Garanto
Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics. Nucleic acid therapeutics (2023)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics (2022)
Andrea López-Martínez, Patricia Soblechero-Martín, Virginia Arechavala-Gomeza
Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy. Methods in molecular biology (Clifton, N.J.) 2434 (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Virginia Arechavala-Gomeza, Alejandro Garanto
Antisense RNA Therapeutics: A Brief Overview. Methods in molecular biology (Clifton, N.J.) 2434 (2022)
Patricia Soblechero-Martín, Andrea López-Martínez, Laura de-la-Puente-Ovejero, Ainara Vallejo-Illarramendi, Virginia Arechavala-Gomeza
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathology and applied neurobiology 47 (6) (2021)
Suzan M Hammond, Annemieke Aarstma-Rus, Sandra Alves, Sven Even F Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela Alessandra Denti, Lourdes Ruiz Desviat, Lucía Echevarría, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T Goyenvalle, Magdalena Guzowska, Irina Kholodnyuk, David R Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke M C van Roon-Mom, Virginia Arechavala-Gomeza
Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO molecular medicine 13 (4) (2021)
Virginia Arechavala-Gomeza, Lidia Gonzalez-Quereda
Special Issue "Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy". Genes 12 (2) (2021)
Patricia Soblechero-Martín, Edurne Albiasu-Arteta, Aina Anton-Martinez, Laura de-la-Puente-Ovejero, Iker Garcia-Jimenez, Gabriela González-Iglesias, Irene Larrañaga-Aiestaran, Andrea López-Martínez, Javier Poyatos-García, Estíbaliz Ruiz-Del-Yerro, Federico Gonzalez, Virginia Arechavala-Gomeza
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening. Scientific reports 11 (1) (2021)
Andrea López-Martínez, Patricia Soblechero-Martín, Laura de-la-Puente-Ovejero, Gisela Nogales-Gadea, Virginia Arechavala-Gomeza
An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I. Genes 11 (9) (2020)
Emma Koehorst, Alfonsina Ballester-Lopez, Virginia Arechavala-Gomeza, Alicia Martínez-Piñeiro, Gisela Nogales-Gadea
The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I. Journal of clinical medicine 9 (12) (2020)
Annemieke Aartsma-Rus, Virginia Arechavala-Gomeza
Why dystrophin quantification is key in the eteplirsen saga. Nature reviews. Neurology 14 (8) (2019)
E Ruiz-Del-Yerro, I Garcia-Jimenez, K Mamchaoui, Virginia Arechavala-Gomeza
Myoblots: dystrophin quantification by in-cell western assay for a streamlined development of Duchenne muscular dystrophy (DMD) treatments. Neuropathology and applied neurobiology 44 (5) (2017)
Caroline Godfrey, Lourdes R Desviat, Bård Smedsrød, France Piétri-Rouxel, Michela A Denti, Petra Disterer, Stéphanie Lorain, Gisela Nogales-Gadea, Valentina Sardone, Rayan Anwar, Samir El Andaloussi, Taavi Lehto, Bernard Khoo, Camilla Brolin, Willeke Mc van Roon-Mom, Aurélie Goyenvalle, Annemieke Aartsma-Rus, Virginia Arechavala-Gomeza
Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO molecular medicine 9 (5) (2017)

Virginia Arechavala-Gomeza.css-eqlu8i{font-size:small;padding-left:4px;} (V Arechavala-Gomeza)

Publication Activity (10 Years)

Top Topics

Top Venues

Virginia Arechavala-Gomeza (V Arechavala-Gomeza)